MHRA publishes a new guidance in case of a hard Brexit

The British Medicines and Healthcare products Regulatory Agency (MHRA) has published a new guidance on the regulation of medicines, medical devices and clinical trials in case of a hard Brexit. The guidance is a useful tool in the preparations for a hard Brexit, the risk of which has just increased after the British Parliament on January 15 rejected the Brexit deal.

The guidance describes how medicines, medical devices and clinical trials are regulated in Britain at pre-sent, and how the areas are expected to be regulated in case of a hard Brexit. For each area, several concrete changes are described which is relevant knowledge for Danish Life Science companies in their preparations for a hard Brexit.

Read the guidance note:
"Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal"

Read more about the consequences of a hard Brexit in this Insight, where Plesner's Brexit Task Force provides an overall view of a number of important legal areas:
"Overview: Consequences of a hard Brexit"

Latest news on Life Science

Life Science